VACCINEX INC (VCNX)

US9186401033 - Common Stock

1.18  -0.08 (-6.35%)

VACCINEX INC

NASDAQ:VCNX (9/27/2023, 11:41:10 AM)

1.18

-0.08 (-6.35%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)08-14 2023-08-14/bmo
Earnings (Next)11-13 2023-11-13/bmo
Ins Owners1.12%
Inst Owners4.7%
Market Cap81.52M
Shares69.08M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts85.71
IPO08-09 2018-08-09
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

VCNX Daily chart

Company Profile

Vaccinex, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Rochester, New York and currently employs 38 full-time employees. The company went IPO on 2018-08-09. The company discovers and develops targeted biotherapeutics to treat diseases with unmet medical needs, including cancer, neurodegenerative diseases and autoimmune disorders. Its platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. SEMA4D antibody platform is the application of its knowledge of SEMA4D biology to develop its lead product candidate pepinemab for the treatment of various diseases and conditions, including cancer and neuroinflammatory and neurodegenerative diseases. Pepinemab’s mechanisms of action block the SEMA4D signal and activate innate physiological mechanisms to respond to tumors or tissue injury. ActivMAb antibody discovery platform is a human antibody discovery platform based on a method for expressing multipass membrane proteins, as well as large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of mammalian pox viruses.

Company Info

VACCINEX INC

1895 Mount Hope Ave

Rochester NEW YORK 14620

P: 15852712700.0

CEO: Maurice Zauderer

Employees: 38

Website: https://www.vaccinex.com/

VCNX News

News Image5 hours ago - Vaccinex, Inc.Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application
News Image22 hours ago - ChartmillWhich stocks are moving on Tuesday?

Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.

News Imagea day ago - ChartmillCurious about what's happening in today's session? Check out the latest stock movements and price changes.

Which stocks are experiencing notable movement on Tuesday?

News Imagea day ago - ChartmillThe market is filled with gapping stocks in Tuesday's session. Let's discover which stocks are showing gap-ups and gap-downs.

Tuesday's session: gap up and gap down stocks

News Imagea day ago - ChartmillTop movers in Tuesday's pre-market session

Pre-market stock analysis on 2023-09-26: top gainers and losers in today's session.

News Imagea day ago - Vaccinex, Inc.Vaccinex Reports Groundbreaking Findings at Medical Conferences Supporting Development of Pepinemab for the Treatment of Neurodegenerative Diseases and Cancer

VCNX Twits

Here you can normally see the latest stock twits on VCNX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example